NCT01058434

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	TKI258

Timeline

• Start date: 2010-05-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2010-01-28
• Last updated: 2020-12-19

Locations

30 sites across 7 countries: United States, Australia, Canada, France, Germany, Netherlands, Turkey (Türkiye)